Capt Delays Importing Paxlovid To Treat Corona Until A Later Date

The Central Agency for Public Tenders has delayed its decision on contracting to a later date in anticipation of the Ministry of Health obtaining regulatory approval for Importing the Paxlovid drug directly from Pfizer at a cost of $9 million.

"Paxlovid" is an antiviral drug that reduces hospitalization risks for "Covid 19" patients by 90 percent, especially among those at high risk.

It's a mixture of pills that can be taken orally and helps minimize the spread of viruses.

As a result of the Ministry's eagerness to import medicines and vaccines approved by international organizations and bodies, and with authority's approval, Paxlovid had been previously recommended by the European Medicines Agency for treating Covid-19 in adults with a significant risk of developing symptoms.

Researchers found that "Paxlovid" inhibits mutant Omicron from multiplying in cells by maintaining plasma concentrations several times above the requirement.

Comments Post Comment

Leave a Comment

Submit